Stelis Biopharma’s CDMO partner receives approval for key ANDA from the USFDA
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
Surana is a chartered accountant with an all-India rank.
Pregabalin Capsules have an estimated market size of US $244 million for twelve months ending Sep 2022 according to IQVIA
Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
The scheme is subject to statutory and regulatory approvals as may be necessary.
Subscribe To Our Newsletter & Stay Updated